Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00094367 | A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study) | PHASE3 | COMPLETED | 900 | — | — | Jul 1, 2004 | Oct 1, 2005 | Sep 30, 2010 | 178 | United States |
| NCT00320307 | Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects | PHASE1 | COMPLETED | 30 | — | — | Sep 1, 2005 | - | Oct 16, 2008 | 1 | United Kingdom |
| Name | Type | Description |
|---|---|---|
| Abacavir/Lamivudine | DRUG | - |
| abacavir | DRUG | - |
Inclusion Criteria: * Have HIV-1 infection. * Had not received any prior HIV treatment for more than 14 days. * At least 1000 copies of HIV-1 RNA. * Willing to provide signed informed consent. Exclusion Criteria: * Enrolled in other investigational drug studies. * Female subjects who are pregnant...